The Spanish group is to invest 16 MM euros to increase output of its parenteral solutions by 30 million units a year

Grifols builds a new solutions factory in Murcia

- The project is expected to receive grants from the Regional Development Agency of Murcia and the Murcia Autonomous Government.
- The new facilities constitute the third stage of Grifols investment plan for Murcia. After Catalonia, this region is the main beneficiary of group investment in Spain.
- The new plant will be built in Torres de Cotillas and is due to be operational in the third quarter of 2011.

Barcelona/Murcia, 9 December 2009.- Grifols, a Spanish holding company specialising in the pharmaceutical-hospital industry and one of the world's leading producers of parenteral solutions, has embarked on a project to build a new intravenous solutions factory in Torres de Cotillas, Murcia. Construction of the site constitutes the third stage of the company's investment plan for the region and, once operational, will enable the group to increase output of its parenteral solutions by 30 million units a year to 50 million. The new plant will boast the latest technology and the most up-to-date automation systems.

Total investment by Grifols amounts to 16 MM euros as per the company's 2008-2012 Investment Plan. However, the project is expected to receive backing from the Regional Development Agency of Murcia in the form of a partial development grant as part of the Ministry of Economy and Financial Affairs’ Regional Incentive Scheme and from the Murcia Autonomous Government through its Technologically Advanced Investment Programme in Strategic Sectors.

The new factory is part of the Murcia-II industrial complex which was opened in 2003 and where the company plans to increase output of its IV solutions in stages. In fact, once operational in the third quarter of 2011, output at the site will have doubled. Upon completion, the two complexes Grifols has in Murcia will occupy over 8,000 m².

Group investment in Murcia ranks second in the country

Grifols has been present in Murcia since 1990 and currently has two industrial complexes in Las Torres de Cotillas which produce IV solutions in plastic bags and blood bags.
Grifols produces 20 million units of IV solutions in flexible bags a year in Murcia to supply the Spanish health network. It also manufactures 6 million blood extraction and storage bags, over half of which are exported.

Today Grifols is one of the leading manufacturers and distributors of parenteral solutions in both flexible and rigid bags in Spain. These are also manufactured at its Parets del Vallès site. Both plants operate according to Good Manufacturing Practice regulations and are accredited with the following environmental, quality and workplace safety certifications: ISO 9001, ISO 14001, ISO 13485 and OHSAS 18001.

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Stock Exchange (“Mercado Continuo”) and is part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments. In terms of raw materials, Grifols has ensured its plasma supply with 80 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.